为了确定来那瓦替尼联合贝伐单抗在经动脉化疗栓塞术（TACE）后治疗原发性肝癌患者的疗效。2020年1月至2021年1月期间，共招募100名原发性肝癌患者，并随机分配到对照组（n = 50）和试验组（贝伐单抗组）（n = 50）。对照组患者在TACE后连续4周接受来那瓦替尼治疗，而试验组患者在TACE前6周接受贝伐单抗治疗，随后继续接受来那瓦替尼治疗4周。于2020年1月开始治疗时和12个月后，对两组患者的干扰素-γ（INF-γ）、白细胞介素-10（IL-10）、可溶性白细胞介素-2受体（sIL-2R）、白细胞介素-12（IL-12）、超氧化物歧化酶（SOD）、总抗氧化能力（TAOC）、谷胱甘肽（GSH）、丙二醛（MDA）、总胆红素（TBil）、天冬氨酸氨基转移酶（AST）、丙氨酸氨基转移酶（ALT）、碱性磷酸酶（ALP）、糖类抗原242（CA242）、CA724、α-胎蛋白（AFP）和癌胚抗原（CEA）的血清浓度进行测定，并与观察到的疗效进行比较。贝伐单抗组的CA242、CEA、CA724和AFP浓度低于对照组（p <0.05）。贝伐单抗组的IL-12和INF-γ水平较高，而IL-10和sIL-2R水平较低（p <0.05）。在贝伐单抗组中，MDA水平较低，而TAOC、SOD和GSH水平较高（p <0.05）。贝伐单抗组的ALT、TBil和AST水平较低，而ALP水平较高（p <0.05）。贝伐单抗组基于肿瘤状态（大小、进展）的治疗反应率高于对照组（p <0.05）。来那瓦替尼联合贝伐单抗在TACE后的原发性肝癌治疗效果显著优于单独使用来那瓦替尼，而且在TACE前6周给予贝伐单抗可以达到更好的疗效。

To determine the therapeutic effects of lenvatinib combined with bevacizumab following transarterial chemoembolization (TACE) in patients with primary liver cancer.100 patients with primary liver cancer were recruited in the period from January 2020 to January 2021 and allocated with randomization into a control group (n = 50) and a test (bevacizumab) group (n = 50). The patients in the control group received lenvatinib for 4 weeks following TACE, whereas those in the test group received bevacizumab for 6 weeks prior to TACE and subsequent therapy with lenvatinib for 4 weeks. The serum concentration of interferon-γ (INF-γ), interleukin-10 (IL-10), soluble interleukin-2 receptor (sIL-2R), interleukin-12 (IL-12), superoxide dismutase (SOD), total antioxidant capacity (TAOC), glutathione (GSH), malondialdehyde (MDA), total bilirubin (TBil), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), carbohydrate antigen 242 (CA242), CA724, α-fetoprotein (AFP) and carcinoembryonic antigen (CEA) were determined in both groups at the commencement of treatment in January 2020 and 12 months later and compared with the observed therapeutic effects.The concentrations of CA242, CEA, CA724, and AFP in the bevacizumab group were lower than those in the control group (p < 0.05). The concentration of IL-12 and INF-γ in the bevacizumab group were higher, but the levels of IL-10 and sIL-2R lower than in the control group (p < 0.05). In the bevacizumab group, the level of MDA was lower, whereas the levels of TAOC, SOD, and GSH were higher than those in the control group (p < 0.05). The bevacizumab group also had lower levels of ALT, TBil, and AST and a higher level of ALP than control group (p < 0.05). The response rate based on tumor status (size, progression) in the bevacizumab group was higher than in the control group (p < 0.05).The therapeutic effects of lenvatinib following TACE in primary liver cancer are significantly greater when combined with bevacizumab administered for 6 weeks prior to TACE.